Supply of products by Aspen Pharmcare Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989 (the "Act") was enacted to ensure the safety and quality of therapeutic goods in Australia. The Act was introduced to address the need for a regulatory framework that governs the supply, manufacturing, advertising, and importation of therapeutic goods, ensuring they meet the required standards of quality, safety, and efficacy. The Act is administered by the Therapeutic Goods Administration (TGA), an agency of the Australian Government Department of Health, and its policy objective is to protect public health by regulating therapeutic goods. In 2013, the delegate of the Secretary of the Department of Health and Ageing gave consent under section 14 and 14A of the Act for the supply of certain pharmaceutical products by Aspen Pharmacare Australia Pty Ltd, subject to specific conditions. The consent addressed the issue of the sponsor's name and address details on the product labels, which did not comply with the Therapeutic Goods Order (TGO) 69. The consent granted to Aspen Pharmacare Australia Pty Ltd allows for the supply of the listed products until December 2013, with the condition that the labels used must bear the name and address of the previous sponsor, GlaxoSmithKline Australia Pty Ltd. Furthermore, the consent ensures that no other changes have been made to the products and that continuous customer contact details are maintained as per the process described in an email dated April 18, 2013.

Scope and Application

The Therapeutic Goods Act 1989, as amended by the 2013 Gazette entry C2013G00993, provides specific consent for Aspen Pharmacare Australia Pty Ltd to supply certain therapeutic goods that do not conform with the Therapeutic Goods Order (TGO) 69. The consent applies to a range of pharmaceutical products listed in the gazette, effective until December 2013. This consent is granted under subsection 15(1) of the Act and is subject to several conditions, including the use of labels bearing the name and address of the previous sponsor, GlaxoSmithKline Australia Pty Ltd, and the maintenance of a process for continuous customer contact as detailed in an email dated April 18, 2013. The Act applies to the specified entities and products within the Commonwealth of Australia, ensuring regulatory oversight of therapeutic goods supplied by Aspen Pharmacare Australia Pty Ltd during this period.

Key Provisions

The Therapeutic Goods Act 1989, as amended, includes specific provisions for the regulation of therapeutic goods, including medicines, medical devices, and other related products. Sections 14 and 14A of the Act pertain to the consent for the supply of certain products, which must meet specific regulatory standards. In this context, on April 19, 2013, the delegate of the Secretary of the Department of Health and Ageing gave consent under subsection 15(1) for Aspen Pharmacare Australia Pty Ltd to supply a list of products (section 14 and 14A Notice). This consent, however, is conditional and applies only until December 2013. These conditions include the use of labels that bear the details of the previous sponsor, GlaxoSmithKline Australia Pty Ltd, and require no other changes to the listed products. Furthermore, the consent mandates that the company maintains a process to ensure continuous customer contact, as detailed in an email dated April 18, 2013. The list of products includes various formulations of amoxicillin, ceftazidime, sumatriptan, lamotrigine, and other therapeutic agents, all subject to these specific regulatory conditions. The Therapeutic Goods Act imposes several obligations on the entities it governs, particularly in the context of supplying therapeutic goods. Firstly, entities must ensure that the products supplied meet the standards set out in the Therapeutic Goods Order (TGO). In this case, the products must conform to TGO 69, with specific attention to the sponsor's name and address details. Additionally, the obligation to use labels bearing the previous sponsor’s details underscores the importance of transparency and traceability in the supply chain. Entities must also ensure that there are no other changes to the products, maintaining the integrity and safety of the therapeutic goods supplied. Furthermore, the requirement for continuous customer contact indicates a commitment to customer service and post-market surveillance, allowing for prompt response to any issues that may arise. Failure to comply with the conditions set forth in the Therapeutic Goods Act can lead to significant consequences. The Act provides for both civil and criminal penalties for non-compliance. Under the civil law, breaches can result in infringement notices with maximum penalties as specified by the Act. Criminal penalties may also apply, with potential fines and imprisonment for more severe breaches. These provisions are intended to enforce compliance and ensure the safety and efficacy of therapeutic goods available in the market.